Effect of Exendin-(9-39) on Fasting Adaptation and Protein Sensitivity

NCT00897676 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

17

Enrollment

OTHER

Sponsor class

Conditions

Congenital Hyperinsulinism

Interventions

DRUG: Exendin-(9-39)
DRUG: placebo

Sponsor

Diva De Leon